OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

G-CSF Prophylaxis Recommended Throughout Chemotherapy in Breast Cancer Patients at Risk for Febrile Neutropenia

November 22, 2013
Jill Stein
Publication
Article
Oncology & Biotech NewsOctober 2013
Volume 7
Issue 10

A Dutch team is recommending the continued use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis throughout all chemotherapy cycles in women with early breast cancer who are at high risk of febrile neutropenia (FN).

Maureen J. Aarts, MD

A Dutch team is recommending the continued use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis throughout all chemotherapy cycles in women with early breast cancer who are at high risk of febrile neutropenia (FN). At present, the approach is standard practice in this population.

The researchers had theorized that it might be possible to omit G-CSF prophylaxis during later chemotherapy cycles as a cost-effectiveness measure given that the risk of FN is highest during the first two chemotherapy cycles, after which the risk rapidly declines and the benefit of G-CSF largely disappears.

In a phase III study with a noninferiority design, Maureen J. Aarts, MD, with Maastricht University Medical Center, and colleagues elsewhere randomized patients to primary G-CSF prophylaxis throughout all chemotherapy cycles or primary G-CSF prophylaxis only in the first two cycles. Pegfilgrastim at a 6-mg fixed dose was administered 24 to 30 hours after chemotherapy administration.

Women with breast cancer were considered eligible for enrollment provided they were fit enough to receive chemotherapy every 3 weeks in the adjuvant, neoadjuvant, or advanced setting, and also had a >20% risk for FN.

The noninferiority hypothesis of the study was that the incidence of FN with primary G-CSF prophylaxis during the first two chemotherapy cycles only would not be inferior to primary G-CSF prophylaxis throughout all chemotherapy cycles, using a noninferiority margin of 7.5% difference.

The study authors, who are with the Dutch Breast Cancer Clinical Trialists’ Group, noted that they believe that their study is the first to use such a design.

The standard and experimental treatment arms were similar with regard to demographic and clinical characteristics. Most subjects were <65 years of age and had an ECOG performance score of 0 to 1.

After 167 eligible patients were enrolled, the independent data monitoring committee recommended that the study be halted prematurely because of an unanticipated high FN rate in the experimental treatment group. Of 83 women assigned to G-CSF during the first two cycles, only 30 (36%) had an FN episode (95% CI, 0.13-0.54). Notably, 24% of episodes occurred in the third cycle. The incidence of FN rapidly decreased thereafter to 7%, 5%, and 2% in cycles four, five, and six, respectively .

Phase III Study of G-CSF Prophylaxis and Febrile Neutropenia Incidence in Patients With Breast Cancer

FN Incidence (%)

Chemotherapy Cycle

Standard Arma

Experimental Armb

1

2

2

2

0

0

3

5

24

4

2

7

5

2

5

6

2

2

Overall Incidence

10

36

aG-CSF administered during chemotherapy cycles 1-6.

bG-CSF administered during chemotherapy cycles 1-2.

FN indicates febrile neutropenia; G-CSF, granulocyte

colony-stimulating factor

Aarts et al pointed out that secondary G-CSF prophylaxis was used in 14 of 20 patients in the experimental arm who developed FN in the third chemotherapy cycle, which was the first cycle without G-CSF prophylaxis. The use of secondary G-CSF prophylaxis may have contributed to the decreasing incidence of FN in later cycles, they said.

In the 84 women who received G-CSF throughout all treatment cycles, eight (10%) experienced an FN episode.

The authors noted that the high FN rate that occurred when primary pegfilgrastim prophylaxis was limited to the first two chemotherapy cycles is as high as that reported in prior studies of docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide (TAC) chemotherapy without primary G-CSF prophylaxis.

Finally, they reported that the introduction of the combined use of anthracyclines and taxanes in the neoadjuvant or adjuvant breast cancer setting has, in part, fueled a marked increase in the number of patients who are eligible for prophylactic G-CSF use. In turn, treatment costs have dramatically increased in The Netherlands by at least 10 to 20 million euros per year.

Aarts MJ, Peters FP, Mandigers CM, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia [published online ahead of print April 26, 2013]. J Clin Oncol. doi:10.1200/JCO.2012.44.6229.

Articles in this issue

G-CSF Prophylaxis Recommended Throughout Chemotherapy in Breast Cancer Patients at Risk for Febrile Neutropenia
G-CSF Prophylaxis Recommended Throughout Chemotherapy in Breast Cancer Patients at Risk for Febrile Neutropenia
Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical Research
Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical Research
Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2
Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2
Breast Cancer Patients Prefer Subcutaneous Trastuzumab
Breast Cancer Patients Prefer Subcutaneous Trastuzumab
Infinity Has High Hopes for PI3K Inhibitor
Infinity Has High Hopes for PI3K Inhibitor
The Affordable Care Act Is Here!… Or Is It?
The Affordable Care Act Is Here!… Or Is It?
Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer
Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer
ALK-Positive Criteria for Determining Crizotinib Use May Fall Short
ALK-Positive Criteria for Determining Crizotinib Use May Fall Short
New Approaches Explored in Relapsed/Refractory Multiple Myeloma
New Approaches Explored in Relapsed/Refractory Multiple Myeloma
Colonoscopy Screening at 10-Year Intervals May Prevent 40% of Colorectal Cancers
Colonoscopy Screening at 10-Year Intervals May Prevent 40% of Colorectal Cancers
Can Foundation Medicine Break Away From the Genomic Testing Pack?
Can Foundation Medicine Break Away From the Genomic Testing Pack?
Managing Melanoma in the Era of Molecular Testing and Targeted Therapy: A Q&A With Ragini Kudchadkar, MD
Managing Melanoma in the Era of Molecular Testing and Targeted Therapy: A Q&A With Ragini Kudchadkar, MD
Unique Considerations With TKIs for Chronic Myelogenous Leukemia
Unique Considerations With TKIs for Chronic Myelogenous Leukemia
Perioperative Breast MRI Does Not Lower Recurrence Risk for Early-Stage Patients
Perioperative Breast MRI Does Not Lower Recurrence Risk for Early-Stage Patients
Novel B-Cell Receptor Signaling Inhibitors Show Promise
Novel B-Cell Receptor Signaling Inhibitors Show Promise
Related Videos
Wesley J. Talcott, MD, MBA
Judy C. Boughey, MD
Francisco J. Esteva, MD, PhD
Stephanie L. Graff, MD
Related Content

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023
Related Content
Advertisement
The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a PARP inhibitor.

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

September 27th 2023
Article
Francois-Clement Bidard, MD, PhD

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023
Podcast
Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

September 24th 2023
Article
Patrick I. Borgen, MD; Laura J. Esserman, MD, MBA; Kelly K. Hunt, MD, FACS, FSSO; Kevin Kalinsky, MD, MS; Lisa A. Carey MD, ScM, FASCO, Steven J. Chmura, MD, PhD

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023
Podcast
Elcin Barker Ergun

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

September 20th 2023
Article
Timothy J. Pluard, MD

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023
Article

Latest Conference Coverage

PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma

At Multiple Dose Levels, Mezigdomide Elicits Responses in Combination With Bortezomib or Carfilzomib in R/R Myeloma

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact